Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kee Woong Kwon

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Vaccine: X|November 15, 2023
Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implicationsHan Gyu Choi, Kee Woong Kwon, Sung Jae Shin
Immunology|February 1, 2017
Virulence-dependent induction of interleukin-10-producing-tolerogenic dendritic cells by Mycobacterium tuberculosis impedes optimal T helper type 1 proliferationHongmin Kim, Kee Woong Kwon, Woo Sik Kim, et al.
NPJ Vaccines|April 10, 2026
An ESAT-6-convergent prime-boost vaccination combining recombinant BCG expressing Mycobacterium marinum ESX-1 and ESAT-6/GLA-SE improves TB protectionKee Woong Kwon, Hongmin Kim, Hagyu Kim, et al.
Biochemical and Biophysical Research Communications|June 13, 2018
Vaccine potential of ESAT-6 protein fused with consensus CD4<sup>+</sup> T-cell epitopes of PE/PPE proteins against highly pathogenic Mycobacterium tuberculosis strain HN878Soo-Young Choi, Kee Woong Kwon, Hongmin Kim, et al.
Frontiers in Microbiology|February 28, 2019
Immunogenicity and Vaccine Potential of InsB, an ESAT-6-Like Antigen Identified in the Highly Virulent <i>Mycobacterium tuberculosis</i> Beijing K StrainWoo Sik Kim, Hongmin Kim, Kee Woong Kwon, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2022
Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis InfectionLee-Han Kim, Soon Myung Kang, Jake Whang, et al.
International Immunopharmacology|April 3, 2024
Adjunctive administration of parabiotic Lactobacillus sakei CVL-001 ameliorates drug-induced toxicity and pulmonary inflammation during antibiotic treatment for tuberculosisHagyu Kim, Eun-Jung Song, Eunsol Choi, et al.
International Journal of Biological Sciences|March 9, 2026
Exploring Host-driven Immunopathological Factors Developing Severe Tuberculosis: Insights from Comparative Mouse ModelsHongmin Kim, Kee Woong Kwon, Hagyu Kim, et al.
Scientific Reports|September 28, 2018
Comparison of immunogenicity and vaccine efficacy between heat-shock proteins, HSP70 and GrpE, in the DnaK operon of Mycobacterium tuberculosisWoo Sik Kim, Jong-Seok Kim, Hong Min Kim, et al.
NPJ Vaccines|March 8, 2024
BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in miceKee Woong Kwon, Han-Gyu Choi, Kwang Sung Kim, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Vaccine: X|November 15, 2023
Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implicationsHan Gyu Choi, Kee Woong Kwon, Sung Jae Shin
Immunology|February 1, 2017
Virulence-dependent induction of interleukin-10-producing-tolerogenic dendritic cells by Mycobacterium tuberculosis impedes optimal T helper type 1 proliferationHongmin Kim, Kee Woong Kwon, Woo Sik Kim, et al.
NPJ Vaccines|April 10, 2026
An ESAT-6-convergent prime-boost vaccination combining recombinant BCG expressing Mycobacterium marinum ESX-1 and ESAT-6/GLA-SE improves TB protectionKee Woong Kwon, Hongmin Kim, Hagyu Kim, et al.
Biochemical and Biophysical Research Communications|June 13, 2018
Vaccine potential of ESAT-6 protein fused with consensus CD4<sup>+</sup> T-cell epitopes of PE/PPE proteins against highly pathogenic Mycobacterium tuberculosis strain HN878Soo-Young Choi, Kee Woong Kwon, Hongmin Kim, et al.
Frontiers in Microbiology|February 28, 2019
Immunogenicity and Vaccine Potential of InsB, an ESAT-6-Like Antigen Identified in the Highly Virulent <i>Mycobacterium tuberculosis</i> Beijing K StrainWoo Sik Kim, Hongmin Kim, Kee Woong Kwon, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2022
Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis InfectionLee-Han Kim, Soon Myung Kang, Jake Whang, et al.
International Immunopharmacology|April 3, 2024
Adjunctive administration of parabiotic Lactobacillus sakei CVL-001 ameliorates drug-induced toxicity and pulmonary inflammation during antibiotic treatment for tuberculosisHagyu Kim, Eun-Jung Song, Eunsol Choi, et al.
International Journal of Biological Sciences|March 9, 2026
Exploring Host-driven Immunopathological Factors Developing Severe Tuberculosis: Insights from Comparative Mouse ModelsHongmin Kim, Kee Woong Kwon, Hagyu Kim, et al.
Scientific Reports|September 28, 2018
Comparison of immunogenicity and vaccine efficacy between heat-shock proteins, HSP70 and GrpE, in the DnaK operon of Mycobacterium tuberculosisWoo Sik Kim, Jong-Seok Kim, Hong Min Kim, et al.
NPJ Vaccines|March 8, 2024
BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in miceKee Woong Kwon, Han-Gyu Choi, Kwang Sung Kim, et al.
Pageof 5